Nucynta
NDC Package 69865-210-01
Package Information
Nucynta is tapentadol is used to help relieve moderate to severe short-term pain (such as pain from an injury or after surgery). Marketed by Depo Nf Sub, Llc, this product is identified by NDC 69865-210 and is authorized under FDA application NDA022304.
Identification & Billing
- RxCUI: 825409 - tapentadol 100 MG Oral Tablet
- RxCUI: 825409 - tapentadol 100 MG (as tapentadol hydrochloride) Oral Tablet
- RxCUI: 825411 - tapentadol 50 MG Oral Tablet
- RxCUI: 825411 - tapentadol 50 MG (as tapentadol hydrochloride) Oral Tablet
- RxCUI: 825413 - tapentadol 75 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69865 - Depo Nf Sub, Llc
- 69865-210 - Nucynta
- 69865-210-01 - 10 BLISTER PACK in 1 CARTON / 10 TABLET, FILM COATED in 1 BLISTER PACK
- 69865-210 - Nucynta
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (69865-210). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69865-210-01 identifies a specific commercial package of 10 blister pack in 1 carton / 10 tablet, film coated in 1 blister pack of Nucynta, labeled by Depo Nf Sub, Llc. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Depo Nf Sub, Llc on June 16, 2017. The current certification is valid through December 31, 2020.
What are the primary indications for this medication?
Tapentadol is used to help relieve moderate to severe short-term pain (such as pain from an injury or after surgery). It belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.
How is this Depo Nf Sub, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69865021001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.